Yahoo
Stockholm - Delayed Quote SEK

Q-linea AB (publ) (QLINEA.ST)

14.90 +0.20 (+1.36%)
At close: October 30 at 12:39:33 PM GMT+1
QLINEA.ST Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for QLINEA.ST
  • Previous Close 14.70
  • Open 14.20
  • Bid 14.90 x --
  • Ask 15.30 x --
  • Day's Range 14.05 - 15.45
  • 52 Week Range 14.05 - 38.42
  • Volume 14,895
  • Avg. Volume 7,221
  • Market Cap (intraday) 282.336M
  • Beta (5Y Monthly) 0.59
  • PE Ratio (TTM) --
  • EPS (TTM) -13.20
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.

qlinea.com

70

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

QLINEA.ST
40.26%
OMX Stockholm 30 Index (^OMX)
13.47%

1-Year Return

QLINEA.ST
40.57%
OMX Stockholm 30 Index (^OMX)
17.56%

3-Year Return

QLINEA.ST
96.41%
OMX Stockholm 30 Index (^OMX)
59.03%

5-Year Return

QLINEA.ST
99.93%
OMX Stockholm 30 Index (^OMX)
42.80%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 2.86M
Earnings --
Profit Margin 0.00%

Q3

FY24

Q4

FY24

Q2

FY25

Q4

FY25

0
1M
2M
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -36.96%

  • Return on Equity (ttm)

    -75.50%

  • Revenue (ttm)

    14.45M

  • Net Income Avi to Common (ttm)

    -152.57M

  • Diluted EPS (ttm)

    -13.20

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    186.77M

  • Total Debt/Equity (mrq)

    4.25%

  • Levered Free Cash Flow (ttm)

    -118.64M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: